Loading
RxSight, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 17 Jan 2025.
RxSight, Inc.: what insiders have been doing
RxSight, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 18 October 2026, brought 9 filings signed by 9 insiders.
The filings describe grants, exercises and other transfers rather than trades on the open market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Over the last twelve months, not one insider purchase of RxSight, Inc. stock was filed. Typically, a trade is published a median of 1 day after it takes place. Section 16 rules allow two business days to file each Form 4.
Across the 5,814 companies tracked on its exchange, the median is 19 filings; at 9 filings, this issuer sits below that mark. Since 2021, the database holds 12 purchases and 28 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 134.5 m USD and net income at -38.9 m USD.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
150
Thresholds
n/a
Buy Volume
€10M
12 ops. · all time
Sell Volume
€19M
28 ops. · all time
Who traded when
BuySaleJesse Anderson Corley2 buys
Shweta Maniar2 sales
Tamara Fountain1 sale
Since the insiders bought
- -68.8%Entry US$30.97 · Close at T+365 US$9.66
- -74.3%Entry US$61.78 · Close at T+365 US$15.89
- +22.0%Entry US$12.83 · Close at T+365 US$15.65
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate RxSight, Inc. Hold (neutral), based on 8 analysts. Average price target: US$7.57.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,067 of 24,161 companies
25.0
score / 100
Value13
Quality37
FCF yld-10%
Earn yld-21%
EV/EBITDA·
ROE-17%
Gross mgn77%
Net mgn-29%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$4.53
Analyst consensus
8 analystsHold
US$5.50Target US$7.57(+67%)US$11.00
Income statement
RevenueUS$134.5M
Gross profitUS$103M77% margin
EBITDA-US$35.6M-26% margin
Net income-US$38.9M-36.8% margin
Valuation
PER (forward)-6.6x
P/Book0.7x
Beta1.14
Balance sheet & cash
Market capUS$188.4M
Total debtUS$11M
Free Cash Flow-US$19.3M
Debt / Equity4%
Profitability & ownership
ROE-17.3%
ROA-10.4%
% insiders6.6%
% institutions104.4%
Last declaration on 16 September 2026
Declarations150 total
35,168 shares@ US$4.340.075% mcap4.0% of flowCommon StockSEC:0001295814-26-000004:0
11,890 shares@ US$6.37080.037% mcap100.0% of flowCommonSEC144:0001950047-26-008359
37,037 sharesCommon StockSEC:0001193125-26-275819:0
30,864 sharesCommon StockSEC:0001193125-26-275834:0
37,037 sharesCommon StockSEC:0001193125-26-275837:0
37,037 sharesCommon StockSEC:0001193125-26-275843:0
12,489 shares@ US$4.130.021% mcap2.6% of flowCommon StockSEC:0001193125-26-164041:0
20,441 sharesCommon StockSEC:0001193125-26-089508:0
6,261 sharesCommon StockSEC:0001193125-26-089500:0
15,096 shares@ US$4.343.3% of flowCommon StockSEC:0001193125-25-220465:0
35,668 shares0Common StockSEC:0000950170-25-102098:0
10,752 sharesCommon StockSEC:0000950170-25-081957:0
10,752 sharesCommon StockSEC:0000950170-25-081956:0
10,752 sharesCommon StockSEC:0000950170-25-081958:0
10,752 sharesCommon StockSEC:0000950170-25-081963:0
10,752 sharesCommon StockSEC:0000950170-25-081961:0
10,752 sharesCommon StockSEC:0000950170-25-081960:0
10,752 sharesCommon StockSEC:0000950170-25-081955:0
10,752 sharesCommon StockSEC:0000950170-25-081953:0
188,002 shares@ US$3.9319.7% of flowCommon StockSEC:0000950170-25-081185:0
7,792 shares@ US$4.33861.8% of flowCommon StockSEC:0000950170-25-054439:0
7,000 shares@ US$25.7145100.0% of flowCommon StockSEC:0000950170-25-038834:0
3,519 shares@ US$30.866213.2% of flowCommon StockSEC:0000950170-25-009239:0
1,443 shares@ US$31.1852.1% of flowCommon StockSEC:0000950170-25-006858:0
Canonical exit: 15 Apr 2025 (T+90)
3,105 shares@ US$15.082.6% of flowCommon StockSEC:0000950170-24-132976:0
25 of 150 declarations
About RxSight, Inc.
RxSight, Inc. is a U.S.-based ophthalmic medical device company listed on the Nasdaq market in the United States under ticker RXST. For French-speaking investors, the equity case is best understood as a focused premium-cataract story built around postoperative refractive customization. The company was originally founded in California in 1997 under the name Calhoun Vision, changed its name to RxSight in October 2016, and later reincorporated in Delaware in 2021. Its principal executive offices are in Aliso Viejo, California.
RxSight’s business is centered almost entirely on its Light Adjustable Lens system, or LAL platform, paired with the Light Delivery Device (LDD) and related accessories. The core innovation is that the lens can be adjusted after cataract surgery, allowing physicians to fine-tune the patient’s vision once healing is underway. That differentiates RxSight from conventional intraocular lenses, which are selected and fixed before surgery. The company currently commercializes two lens variants, LAL and LAL+, with the latter designed to provide a modest extension of depth of focus. In commercial terms, RxSight offers an integrated workflow: implant, in-office light-treatment device, consumables, and a clinical ecosystem built around the adjustment process.
Read moreShow less
From a competitive standpoint, RxSight occupies a specialized but attractive niche in premium cataract care. Management describes the system as the first and only commercially available IOL technology that can be adjusted after surgery. That uniqueness is the company’s main moat and supports premium positioning with surgeons and patients seeking more precise refractive outcomes. The trade-off is that adoption depends on surgeon training, practice workflow integration, and continued expansion of the installed base of LDD devices. As a result, RxSight’s opportunity is tied not just to lens sales, but also to procedure growth across its network of trained practices.
Recent developments have been important for both commercial momentum and geographic expansion. In February 2026, the company said more than 300,000 LAL procedures had been performed since launch, the installed base of LDDs had reached 1,134, and regulatory approval had been received in Australia, broadening its international addressable market. RxSight also said FDA post-approval study results were accepted for publication in the Journal of Cataract & Refractive Surgery. The company continues to hold regulatory approvals across North America, Europe, Singapore, South Korea, and Australia. For investors, RxSight remains a commercial-stage medtech growth story: differentiated intellectual property, an expanding clinical base, and international optionality, but with execution risk still centered on sales force productivity, surgeon adoption, and operating leverage.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
